Document is current
Any future updates will be listed below
-
Authors
Chen, Jennifer H.
Addanki, Sridevi
Roy, Dhruvajyoti
Bassett, Roland
Kalashnikova, Ekaterina
Spickard, Erik
Kuerer, Henry M.
Meas, Salyna
Sarli, Vanessa N.
Korkut, Anil
White, Jason B.
Rauch, Gaiane M.
Tripathy, Debu
Arun, Banu K.
Barcenas, Carlos H.
Yam, Clinton
Sethi, Himanshu
Rodriguez, Angel A.
Liu, Minetta C.
Moulder, Stacy L.
Lucci, Anthony
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 24 July 2024
First Online: 16 August 2024
Declarations
:
: The study protocol was approved by the ethics committee at University of Texas MD Anderson Cancer Center (Protocol 2014–0185) and consent was obtained from all patients prior to participation in the study. All procedures were conducted in accordance with the principles outlined in the Declaration of Helsinki.
: Not applicable.
: E.K., E.S., H.S., A.R., and M.C.L. are employees of Natera, Inc. and have stock/option to hold stock in the company. Additional COIs for M.C.L: Grants/Contracts: Funding to Institution (Mayo) from: Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, Tesaro; Travel Support Reimbursement from AstraZeneca, Genomic Health, Ionis; Ad hoc advisory board meetings. All funds to Mayo Clinic. No personal compensation from: AstraZeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, Syndax.
